Latest News for: orexin receptor

Edit

Major Depressive Disorder Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ...

GetNews 11 Apr 2025
... (NAS) GABAA receptor positive allosteric modulator (PAM) ... Seltorexant is an innovative selective orexin 2 receptor antagonist under development for the treatment of insomnia and related mood disorders.
Edit

NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity ...

ACCESSWIRE 31 Mar 2025
Through a strategic licensing agreement with Aexon Labs, NLS is advancing a portfolio of non-sulfonamide dual orexin receptor agonists (DOXA), including AEX-2 and AEX-41, designed to restore ...
  • 1
×